2011 - Outpatient treatment was noninferior to inpatient treatment for preventing recurrent VTE in low-risk patients with acute PE

Bates, Shannon M.; Guyatt, Gordon H.
October 2011
ACP Journal Club;10/18/2011, Vol. 155 Issue 4, p1
Academic Journal
The article focuses on randomized, controlled, noninferiority trial which compared the efficacy of outpatient and inpatient treatment in preventing recurrent venous thromboembolism (VTE), major bleeding and mortality in low-risk patients with acute, symptomatic pulmonary embolism (PE). Study authors concluded that outpatient and inpatient treatment offer the same benefits in terms of preventing recurrent VTE and all-cause mortality at 90 days.


Related Articles

  • Fondaparinux Sodium: A Review of its Use in the Treatment of Acute Venous Thromboembolism. Robinson, Dean M.; Wellington, Keri; Badimon, J. J.; Büller, H. R.; Gallus, A.; Hyers, T. M.; Walenga, J. M.; Piovella, F. // American Journal of Cardiovascular Drugs;2005, Vol. 5 Issue 5, p335 

    Fondaparinux sodium (fondaparinux) is a synthetic sulfated pentasaccharide anticoagulant developed from the antithrombin binding moiety of heparin. Through the activation of antithrombin it inhibits Factor Xa, the activation of thrombin, and the subsequent coagulation cascade. Fondaparinux is...

  • Management of venous thromboembolism: an update. Piran, Siavash; Schulman, Sam // Thrombosis Journal;2016 Supplement, Vol. 14, p107 

    Venous thromboembolism (VTE), which constitutes pulmonary embolism and deep vein thrombosis, is a common disorder associated with significant morbidity and mortality. Landmark trials have shown that direct oral anticoagulants (DOACs) are as effective as conventional anticoagulation with vitamin...

  • Treating pulmonary embolism at home? Egan, Mari; Rowland, Kate // Clinician Reviews;Dec2012, Vol. 22 Issue 12, p32 

    The article focuses on the outpatient treatment of pulmonary embolism (PE) in low-risk patients. Low-molecular-weight heparin (LMWH) as allowing the treatment of venous thromboembolism (VTE) without hospitalization is presented for low-risk patients wherein LMWH is administered subcutaneously...

  • Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. Shirley, Matt; Dhillon, Sohita // Drugs;Nov2015, Vol. 75 Issue 17, p2025 

    Edoxaban (Lixiana, Savaysa) is an oral, direct factor Xa inhibitor which has recently been approved for use in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) [collectively, venous thromboembolism (VTE)] and for the prevention of recurrent VTE. This article reviews the...

  • Nové perorálne antikoagulanciá v liečbe a sekundárnej prevencii venóznej tromboembolizácie v súčasnej klinickej praxi: aký je odkaz z randomizovaných klinických Å¡túdií? Remková, A. // Cardiology Letters;2016, Vol. 25 Issue 1, p22 

    The objective of anticoagulant treatment in patients with acute venous thromboembolism (VTE) is prevention of early death and recurrent symptomatic deep venous thrombosis/pulmonary embolism. Heparins and vitamin K antagonists (VKA) have been the mainstay of prevention and treatment of VTE for...

  • Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Gómez-Outes, Antonio; Luisa Suárez-Gea, M.; Lecumberri, Ramón; Terleira-Fernández, Ana Isabel; Vargas-Castrillón, Emilio // Vascular Health & Risk Management;2014, Vol. 10, p627 

    Pulmonary embolism (PE) is a relatively common cardiovascular emergency. PE and deep vein thrombosis (DVT) are considered expressions of the same disease, termed as venous thromboembolism (VTE). In the present review, we describe and meta-analyze the efficacy and safety data available with the...

  • Prevention of venous thromboembolism: Clinical and economic implications. Spyropoulos, Alex C. // American Journal of Health-System Pharmacy;10/15/2006 Supplement, Vol. 63, pS3 

    The article discusses the prevention of the risk of acquiring venous thromboembolism (VTE) by people living in the U.S. The VTE has been the major burden in the country's health care system, with an estimated annual incidence of 0.1% for the first time VTE. This disease has been leading to a...

  • Clinical Experience with Bemiparin. Rico, José Ignacio Abad; Sánchez, Francisco S. Lozano; Rocha, Eduardo // Drugs;2010 Supplement 2, Vol. 70, p25 

    Subcutaneous bemiparin has been evaluated for the prevention of venous thromboembolism (VTE) in moderate to high-risk patients undergoing surgery, and for the acute and long-term treatment of established VTE. General and orthopaedic surgery is associated with VTE incidence rates of 15-60% in the...

  • Emerging options in the treatment of venous thromboembolism. Nutescu, Edith A. // American Journal of Health-System Pharmacy;12/1/2004 Supplement, Vol. 61, pS12 

    Purpose: The long-term consequences of recurrent venous thromboembolism (VTE) and post-thrombotic syndrome, clinical profiles of traditional and novel antithrombotic agents used to treat VTE, current treatment recommendations for acute symptomatic VTE, clinical experience with newer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics